Monopost (Latanoprost)

Latanoprost, the active ingredient in Monopost, is a prostaglandin analog presented as eye drops for ocular (topical) use. It lowers intra‑ocular pressure and is prescribed for primary open‑angle glaucoma and ocular hypertension in adult patients to help preserve visual function. The medication works by enhancing the outflow of fluid through the uveoscleral pathway, thereby reducing pressure on the optic nerve.

GNH USA supplies Monopost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with consistent quality and regulatory compliance.

Latanoprost is used to lower intra‑ocular pressure in glaucoma‑related conditions.

Primary open‑angle glaucoma: reduces intra‑ocular pressure to help prevent optic nerve damage. Ocular hypertension: lowers intra‑ocular pressure to reduce risk of progression to glaucoma. Secondary open‑angle glaucoma: assists in pressure control when other therapies are insufficient.

Latanoprost may cause ocular and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris darkening: gradual brownish pigmentation. - Eye irritation: foreign‑body sensation or itching. - Blurred vision: transient visual disturbance. - Periorbital skin darkening: mild hyperpigmentation around the eye.

Serious or Rare Side Effects: - Severe eye pain: may indicate inflammation. - Vision loss: sudden decrease in visual acuity. - Uveitis: intra‑ocular inflammation requiring medical attention. - Macular edema: swelling of the central retina. - Allergic reaction: swelling, rash, or hives. - Corneal ulcer: open sore on the cornea.

Before prescribing Latanoprost, clinicians should consider several safety and handling precautions.

Pregnancy: safety not established; use only if potential benefit justifies risk. Breastfeeding: unknown excretion; caution advised. Ocular surgery: postpone treatment at least four weeks before and after procedure. Active ocular inflammation: avoid use until inflammation resolves. Contact lens wear: discontinue lenses during treatment as drug may absorb. Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic or systemic agents, influencing efficacy or safety.

Major Interactions (Avoid): - Other prostaglandin analog eye drops: combined use increases risk of ocular side effects. - Systemic carbonic anhydrase inhibitors: may cause excessive intra‑ocular pressure reduction.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive IOP‑lowering effect; monitor pressure. - Alpha‑agonist eye drops: potential additive hypotensive effect. - Systemic non‑steroidal anti‑inflammatory drugs (NSAIDs): may diminish prostaglandin activity. - Anticholinergic eye drops: possible alteration of ocular dynamics.